BIOLOGY OF AGING GROUP

ADVANCED THERAPIES AREA

Researchers
External Collaborator Researchers and Researchers in Training
  • Dr. Blanca López-Íbor (Hospital HM Montepríncipe)
  • Marta Osuna, MD (predoctoral, Fundación Jerôme Lejeune and Fundación Álvaro Entrecanales Grant, Hospital HM Montepríncipe)
  • Álvaro Soto Sainz (Spanish Association Against Cancer Laboratory Internship Grant)
Research Summary

Our research group is focused on the study of genes and biological processes whose alterations lead to pathologies with molecular and physiological bases common to the natural aging process. In particular, and from a translational approach, we focus on investigating the molecular basis of the differential susceptibility to cancer in people with Down syndrome, who also develop premature aging. 

Advances in the field of Genetics, reflected in early diagnosis of diseases and the development of efficient and specific therapies, have contributed significantly to an increase in life expectancy. At the same time, pathologies associated with aging have gradually increased. These deleterious changes that are associated with the natural aging process, sometimes , usually manifest themselves at an early age due, in this case, to congenital alterations that trigger genetic diseases of varying degrees of severity. The study of genes and biological processes whose alterations lead to these pathologies with molecular and physiological bases in common with the natural aging process can constitute a source of knowledge that can contribute both to the treatment of these diseases and to the delay or improvement of those physiological processes associated with the aging of the organism. Likewise, a better understanding of the biology of aging can contribute to improving the quality of life of our elders and, therefore, of society. In particular, we have focused on dyskeratosis congenita and differential susceptibility to tumors in patients with Down syndrome. In the search for advanced therapies and adjuvants in cancer treatments, one of our research lines evaluates the effect of certain polyphenols in pediatric tumor lines, in collaboration with the Microbial Biotechnology Group of the UFV. 

The research lines of the group also have a strong ethical component; we are firmly convinced that there is a need for powerful research in diseases that due to lack of effective and safe therapies put people’s lives at risk, in their different stages, and in this way we could contribute to the welfare of our society.  

Grado Genetica Biology of Aging Advanced Therapies Area Estudiar en Universidad Privada Madrid
Projects funded in recent years
  • “Study of differential susceptibility to cancer in children with Down syndrome as a basis for an antitumor therapeutic approach based on miRNAs” Universidad Francisco de Vitoria (2024-2025).
  • “Effect of the polyphenols quercetin and catechin on tumors of interest in pediatrics.” Universidad Francisco de Vitoria (2025-2026). In collaboration with the Microbial Biotechnology Group of the UFV
  • “Molecular causes of protection against solid tumors in people with Down Syndrome as a basis for antitumor therapy”. Fundación Mutua Madrileña (2023-2025).
  • “Differential protection against medulloblastoma in children with Down syndrome as a basis for an antitumor therapy based on miRNAs” Universidad Francisco de Vitoria (2022-2023).
  • “Study of telomeric dysfunction caused by TIN2 deficiency and rescue by gene editing as a possible therapy for telomeropathies.” Universidad Francisco de Vitoria (2020-2021)
Recent high impact publications
  • “Questions and answers in the management of children with medulloblastoma over the time. How did we get here? A systematic review.” Osuna-Marco MP, Martín-López LI, Tejera ÁM, López-Ibor B. Front Oncol. 2023 Jun 29;13:1229853. doi: 10.3389/fonc.2023.1229853.  
  • “Ten Reasons Why People With Down Syndrome are Protected From the Development of Most Solid Tumors -A Review.” Osuna-Marco MP, López-Barahona M, López-Ibor B, Tejera ÁM. Front Genet. 2021 Nov 5;12:749480. doi: 10.3389/fgene.2021.749480.  
  •  “A synthetic mRNA cell reprogramming method using CYCLIN D1 promotes DNA repair generating improved genetically stable human induced pluripotent stem cells”. Alvarez-Palomo AB,  Requena-Osete J, Delgado-Morales R, Moreno-Manzano V, Grau-Bove C, Tejera AM, Otero MJ, Barrot  C, Santos-Barriopedro I, Vaquero A , Mezquita-Pla J, Moran  S, Hobeich Naya C, Garcia-Martínez I, Vidal Pérez  F, Blasco  MA, Esteller  M, Edel  MJ. Stem Cells. 2021 Feb 23, doi: 10.1002/stem.3358. 
  • “Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres.” Povedano JM, Martinez P, Serrano R, Tejera Á, Gómez-López G, Bobadilla M, Flores JM, Bosch F, Blasco MA. Elife. 2018 Jan 30;7:e31299.  
  • “AAV9-mediated telomerase activation does not accelerate tumorigenesis in the context of oncogenic K-Ras-induced lung cancer.” Muñoz-Lorente MA, Martínez P, Tejera Á, Whittemore K, Moisés-Silva AC, Bosch F, Blasco MA. PLoS Genet. 2018 Aug 16;14(8):e1007562.